At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AMGN Amgen
Not Yet Opened 12-16 16:00:00 EST
326.74
+1.43
+0.44%
盘后326.54
-0.20-0.06%
19:58 EST
High327.34Low323.02Vol2.64M
Open324.82D1 Closing325.31Amplitude1.33%
Mkt Cap175.94BTradable Cap175.46BTotal Shares538.48M
T/O860.34MT/O Rate0.49%Tradable Shares536.99M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

GSK wins US approval for twice-yearly asthma drug
Reuters  ·  08:01
GSK wins US approval for twice-yearly asthma drug
What Amgen (AMGN)'s Expanded UPLIZNA Approval in Generalized Myasthenia Gravis Means For Shareholders
Simply Wall St.  ·  12-16 13:12
What Amgen (AMGN)'s Expanded UPLIZNA Approval in Generalized Myasthenia Gravis Means For Shareholders
Goldman Sachs, Amgen Share Gains Lead Dow's 125-Point Climb
Dow Jones  ·  12-15 22:45
Goldman Sachs, Amgen Share Gains Lead Dow's 125-Point Climb
Spruce Biosciences Appoints Keli Walbert to Board of Directors
Reuters  ·  12-15 21:01
Spruce Biosciences Appoints Keli Walbert to Board of Directors
Amgen Is Maintained at Equal-Weight by Morgan Stanley
Dow Jones  ·  12-13
Amgen Is Maintained at Equal-Weight by Morgan Stanley
BRIEF-EMA's CHMP Recommended Granting Marketing Authorisation For Moderna's Mnexspike
Reuters  ·  12-12
BRIEF-EMA's CHMP Recommended Granting Marketing Authorisation For Moderna's Mnexspike
Morgan Stanley Adjusts Amgen Price Target to $304 From $329, Maintains Equalweight Rating
MT Newswires Live  ·  12-12
Morgan Stanley Adjusts Amgen Price Target to $304 From $329, Maintains Equalweight Rating
Ema's Chmp: Recommends Extension of Therapeutic Indication for Nucala
THOMSON REUTERS  ·  12-12
Ema's Chmp: Recommends Extension of Therapeutic Indication for Nucala
Ema's Chmp: Concludes Referral for Melatomed, Recommends Marketing Authorisation Can Be Granted
THOMSON REUTERS  ·  12-12
Ema's Chmp: Concludes Referral for Melatomed, Recommends Marketing Authorisation Can Be Granted
FACTBOX-Weight-loss drug developers line up to tap lucrative market as competition heats up
Reuters  ·  12-12
FACTBOX-Weight-loss drug developers line up to tap lucrative market as competition heats up
Amgen Gets FDA Approval for Autoimmune Disorder Treatment
Dow Jones  ·  12-12
Amgen Gets FDA Approval for Autoimmune Disorder Treatment
FDA Approves Amgen’s Uplizna for Generalized Myasthenia Gravis in Adults
Reuters  ·  12-12
FDA Approves Amgen’s Uplizna for Generalized Myasthenia Gravis in Adults
FDA Approves Uplizna® for Adults With Generalized Myasthenia Gravis
THOMSON REUTERS  ·  12-12
FDA Approves Uplizna® for Adults With Generalized Myasthenia Gravis
Weight-Loss Drugmakers' Stocks Jump. Structure Therapeutics up over 6%; Novo Nordisk, Roche up Nearly 4%; Eli Lilly up Slightly
Tiger Newspress  ·  12-10
Weight-Loss Drugmakers' Stocks Jump. Structure Therapeutics up over 6%; Novo Nordisk, Roche up Nearly 4%; Eli Lilly up Slightly
Amgen Inc. : Wells Fargo Raises Target Price to $325 From $300
THOMSON REUTERS  ·  12-10
Amgen Inc. : Wells Fargo Raises Target Price to $325 From $300
U.S. RESEARCH ROUNDUP-JP Morgan, Pepsico, Pfizer
Reuters  ·  12-10
U.S. RESEARCH ROUNDUP-JP Morgan, Pepsico, Pfizer
Amgen Inc : HSBC Raises Target Price to $425 From $381
THOMSON REUTERS  ·  12-10
Amgen Inc : HSBC Raises Target Price to $425 From $381
Amgen Inc. Stock Underperforms Tuesday When Compared To Competitors
Dow Jones  ·  12-10
Amgen Inc. Stock Underperforms Tuesday When Compared To Competitors
Amgen Boosts Dividend by 5.9%
Dow Jones  ·  12-10
Amgen Boosts Dividend by 5.9%
Amgen Raises Quarterly Dividend to $2.52 a Share From $2.38, Payable March 6 to Shareholders of Record as of Feb. 13
MT Newswires Live  ·  12-10
Amgen Raises Quarterly Dividend to $2.52 a Share From $2.38, Payable March 6 to Shareholders of Record as of Feb. 13

Introduction

Company Name.
Amgen
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
Issue price:
--